Triple-negative breast cancers are a heterogeneous group and may not always be associated with lymph node spread, a new study shows.
The study of 145 triple negative breast cancers (i.e, cancer which is estrogen receptor-negative, progesterone receptor-negative and HER2-negative) in 128 women found that about 23% were moderate or low-grade lesions, said Cecilia Mercado, MD, of New York University School of Medicine, and an author of the study.
Triple negative breast cancer is found in about 15% of breast cancer patients and the patients are usually younger.
The study found that 11 of the 145 cancers had a low histologic grade. Only one of these patients had evidence that their cancer had spread into their lymph nodes. Twenty-three cancers were moderate grade lesions; only five of these 23 had spread into the lymph nodes. That compares to 37 of 111 cancers with a high histologic grade which had lymph node metastases, Dr. Mercado said.
“Our preliminary results show that triple negative breast cancers are a heterogeneous group. Although many are high grade lesions, some are moderate or low grade demonstrating a lower rate of lymph node metastasis,” Dr. Mercado said.
Source: American Roentgen Ray Society
Related stories:
New approach to genetic testing could halve deaths from inherited bowel cancer
Changing the approach to genetic screening for cancers in Australia could effectively halve deaths caused by an inherited form of bowel cancer, says a University of Melbourne expert.
Study examines association between caffeine consumption and breast cancer risk
Caffeine consumption does not appear to be associated with overall breast cancer risk, according to a report in the October 13 issue of
Archives of Internal Medicine. However, there is a possibility of increased risk for women with benign breast disease or for tumors that are hormone-receptor negative or larger than 2 centimeters.
Scientists develop new cancer-killing compound from salad plant
(PhysOrg.com) -- Researchers at the University of Washington have updated a traditional Chinese medicine to create a compound that is more than 1,200 times more specific in killing certain kinds of cancer cells than currently available drugs, heralding the possibility of a more effective chemotherapy drug with minimal side effects.
Researcher Looks For Better Way to Kill Cancer Cells
Physics Professor Diandra Leslie-Pelecky brought more with her when she arrived at UT Dallas than expertise in nanotechnology and shiny behemoth lab equipment. She brought an award for $84,000 from the National Institutes of Health via the Cleveland Clinic.
Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist
Essential for life in higher animals, vitamin D, once linked to only bone diseases such as rickets and osteoporosis, is now recognized as a major player in contributing to overall human health, emphasizes UC Riverside's Anthony Norman, an international expert on vitamin D.
New findings may improve treatment of inherited breast cancer
Scientists have identified some of the elusive downstream molecules that play a critical role in the development and progression of familial breast cancer. The research, published by Cell Press in the October 10th issue of the journal
Molecular Cell, also identifies a compound found in grapes and red wine as an excellent candidate for treatment of some forms of breast cancer.
Tamoxifen chemoprevention tied to early detection of breast cancer
The drug tamoxifen does not prevent or treat estrogen receptor (ER) negative breast cancer, but it can make the disease easier to find, researchers report in the Oct. 1
Journal of the National Cancer Institute.
Herbal menopause therapy a good fit for breast cancer patients?
When it comes to understanding the effectiveness and safety of using herbal therapies with other drugs, much is unknown. Now, a University of Missouri researcher will study how black cohosh - an herbal supplement often used to relieve hot flashes in menopausal women - interacts with tamoxifen, a common drug used to treat breast cancer.